David C. Myles

Insider Reports History

Entity
Individual
Location
C/O Olema Pharmaceuticals, Inc., 512 2 Nd Street, 4 Th Floor, San Francisco, CA
Signature
/s/ Shane Kovacs, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by David C. Myles:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Olema Pharmaceuticals, Inc. CH. DISCOV. & NON-CLIN DEV OFF Common Stock 598K $5.62M $9.39 Dec 11, 2024 Direct
Olema Pharmaceuticals, Inc. CH. DISCOV. & NON-CLIN DEV OFF Common Stock 155K $1.45M $9.39 Dec 9, 2024 Indirect
Olema Pharmaceuticals, Inc. CH. DISCOV. & NON-CLIN DEV OFF Stock Option (Right to Buy) 195K Feb 1, 2024 Direct

Insider Reports Filed by David C. Myles

Symbol Company Period Transactions Value $ Form Type Date Filed Role
OLMA Olema Pharmaceuticals, Inc. Dec 9, 2024 4 -$235K 4 Dec 11, 2024 CH. DISCOV. & NON-CLIN DEV OFF
OLMA Olema Pharmaceuticals, Inc. Feb 1, 2024 1 $0 4 Feb 5, 2024 CH. DISCOV. & NON-CLIN DEV OFF
OLMA Olema Pharmaceuticals, Inc. Nov 20, 2023 4 -$196K 4 Nov 22, 2023 CH. DISCOV. & NON-CLIN DEV OFF
OLMA Olema Pharmaceuticals, Inc. Nov 8, 2023 1 -$3.52K 4 Nov 13, 2023 CH. DISCOV. & NON-CLIN DEV OFF
OLMA Olema Pharmaceuticals, Inc. Nov 1, 2023 3 -$161K 4 Nov 3, 2023 CH. DISCOV. & NON-CLIN DEV OFF
OLMA Olema Pharmaceuticals, Inc. Sep 19, 2023 1 -$253K 4 Sep 21, 2023 CH. DISCOV. & NON-CLIN DEV OFF
OLMA Olema Pharmaceuticals, Inc. Feb 1, 2023 1 $0 4 Feb 2, 2023 Chief Development Officer
OLMA Olema Pharmaceuticals, Inc. Feb 1, 2022 1 $0 4 Feb 3, 2022 CHIEF DEVELOPMENT OFFICER
OLMA Olema Pharmaceuticals, Inc. Dec 10, 2021 1 -$103K 4 Dec 14, 2021 CHIEF DEVELOPMENT OFFICER